CHIR99021

Code: sml1046-5mg D2-231

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

CHIR99021 has been used:in cocktail with small molecules to convert human lung fibroblast cells into neuronsas a culture medium supplement in potassium supplement...


en savoir plus

Votre prix
£110.00 5MG

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

CHIR99021 has been used:in cocktail with small molecules to convert human lung fibroblast cells into neuronsas a culture medium supplement in potassium supplemented simplex optimization medium (KSOM) for the culture of blastocystsfor chronic inhibition of GSK-3 to investigate its role in corticogenesis

Biochem/physiol Actions

CHIR99021 is a very potent inhibitor of Glycogen synthase kinase 3 (GSK3, IC50 values for GSK3α and GSK3β = 10 and 6.7 nM, respectively). There is no cross-reactivity against CDKs. CHIR99201 potentiates self-renewal of human and mouse embryonic stem cells, and enhances reprogramming of somatic cells into stem cells.

General description

CHIR99021 is an aminopyrimidine derivative. CHIR99021 promotes self-renewal potential of embryonic stem cells (ESCs) of mice by inhibiting glycogen synthase kinase-3 (GSK-3) activity and potentiates the upregulation of β-catenin and c-Myc functions. CHIR99021 promotes self-renewal of ESCs by modulating transforming growth factor β (TGF-β), Notch and mitogen-activated protein kinases (MAPK) signaling pathways. CHIR99021 is an agonist of wingless/integrated (wnt) signalling, upregulates cyclinA expression and promotes cell proliferation in non-small-cell lung cancer (NSCLC) cell lines.

Packaging

5, 25 mg in glass bottle

assay≥98% (HPLC)
colorwhite to light brown
formpowder
Quality Level100
SMILES stringClC(C=C1Cl)=CC=C1C2=NC(NCCNC(N=C3)=CC=C3C#N)=NC=C2C4=NC(C)=CN4
solubilityDMSO: 2 mg/mL, clear (warmed)
storage temp.−20°C
Code
Description
Unité de vente
Prix annoncé
Qté
SML1046-25MG
Unité:25MG
Prix annoncé: £435.00
Source:Prix annoncé
Cas Number252917-06-9
Ce produit répond aux critères suivants: